EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 35 / Numéro 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 937-945 Références
Open Access
Numéro
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 937 - 945
Section La révolution des anticorps modulateurs de la réponse immunitaire en oncologie
DOI https://doi.org/10.1051/medsci/2019225
Publié en ligne 6 janvier 2020
  1. Fridman WH. Historique de l’immunothérapie. Changement de paradigme ? Bull Cancer (Paris) 2016; 103: S122–6. [CrossRef] [Google Scholar]
  2. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008 ; 26: 527–534. [CrossRef] [PubMed] [Google Scholar]
  3. Gregor RT. Vitiligo and malignant melanoma: a significant association?. South Afr Med J 1976 ; 50: 1447–1449. [Google Scholar]
  4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 ; 364: 2517–2526. [Google Scholar]
  5. Maio M, Grob J-J, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015 ; 33: 1191–1196. [CrossRef] [PubMed] [Google Scholar]
  6. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015 ; 372: 320–330. [Google Scholar]
  7. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015 ; 372: 2521–2532. [Google Scholar]
  8. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (Keynote-006). Lancet 2017 ; 390: 1853–1862. [CrossRef] [PubMed] [Google Scholar]
  9. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018 ; 19: 1480–1492. [CrossRef] [PubMed] [Google Scholar]
  10. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018 ; 378: 1789–1801. [Google Scholar]
  11. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017 ; 377: 1824–1835. [Google Scholar]
  12. Amaria RN, Reddy SM, Tawbi HA, et al. Publisher correction: neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018 ; 24: 1942. [Google Scholar]
  13. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non–small cell lung cancer, version 4.2016. J Natl Compr Canc Netw 2016 ; 14: 255–264. [Google Scholar]
  14. Duruisseaux M, Berghmans T. Évolution et révolution dans la prise en charge systémique des cancers du poumon. La nouvelle place des immunothérapies. Rev Mal Respir 2018 ; 35: 101–102. [CrossRef] [PubMed] [Google Scholar]
  15. OPDIVO: indications en France en août 2019. Paris: ANSM, 2019. [Google Scholar]
  16. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015 ; 373: 123–135. [Google Scholar]
  17. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015 ; 373: 1627–1639. [Google Scholar]
  18. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017 ; 389: 255–265. [CrossRef] [PubMed] [Google Scholar]
  19. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (Keynote-010): a randomised controlled trial. Lancet 2016 ; 387: 1540–1550. [CrossRef] [PubMed] [Google Scholar]
  20. KEYTRUDA: indications en France en juin 2019. Paris: ANSM, 2019. [Google Scholar]
  21. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 2016 ; 375: 1823–1833. [Google Scholar]
  22. Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 Keynote-042 study. J Clin Oncol 2018; 36: LBA4. [Google Scholar]
  23. Jimenez Alguilar E, Gainor J, Kravets S, et al. MA04.05 outcomes in NSCLC patients treated with first-line pembrolizumab and a PD-L1 TPS of 50–74% vs 75–100% or 50–89% vs 90–100%. J Thorac Oncol 2018; 13: S367–8. [Google Scholar]
  24. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med 2018 ; 379: 2040–2051. [Google Scholar]
  25. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 2018 ; 378: 2078–2092. [Google Scholar]
  26. Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol 2018; 36: LBA9000. [Google Scholar]
  27. WCLC 2018. IMpower132: Atezolizumab plus carboplatin and pemetrexed in stage IV nonsquamous NSCLC. The ASCO Post, 2019. [Google Scholar]
  28. TECENTRIQ: indications en Europe en août 2019. Amsterdam: European Medicines Agency, 2019. [Google Scholar]
  29. Ryu R, Ward KE. Atezolizumab for the first-line treatment of non-small cell lung cancer (NSCLC): current status and future prospects. Front Oncol 2018; 8. [Google Scholar]
  30. Socinski MA, Jotte RM, Cappuzzo F, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J Clin Oncol 2018 ; 36: 9002. [Google Scholar]
  31. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018 ; 378: 2288–2301. [Google Scholar]
  32. Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018 ; 378: 2093–2104. [Google Scholar]
  33. IMFIZI: indications en Europe en août 2019. Amsterdam: European Medicines Agency, 2018. [Google Scholar]
  34. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018 ; 379: 2342–2350. [Google Scholar]
  35. Horn L, Mansfield AS, Szcze˛sna A, et al. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018 ; 379: 2220–2229. [Google Scholar]
  36. Alley EW, Katz SI, Cengel KA, et al. Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl Lung Cancer Res 2017 ; 6: 212–219. [CrossRef] [PubMed] [Google Scholar]
  37. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019 ; 20: 239–253. [CrossRef] [PubMed] [Google Scholar]
  38. Forde PM, Scherpereel A, Tsao AS. Use of Immune Checkpoint Inhibitors in Mesothelioma. Curr Treat Options Oncol 2019 ; 20: 18. [CrossRef] [PubMed] [Google Scholar]
  39. Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018 ; 16: 807–821. [Google Scholar]
  40. Scherpereel A, Wallyn F, Albelda SM, et al. Novel therapies for malignant pleural mesothelioma. Lancet Oncol 2018 ; 19: e161–e172. [CrossRef] [PubMed] [Google Scholar]
  41. Fridman WH, Teillaud JL. De la traversée du désert au prix Nobel de Physiologie ou Médecine décerné à James Allison et Tasuku Honjo: la longue marche de l’immunothérapie des cancers - Entretien avec Wolf Hervé Fridman. Med Sci (Paris) 2019 ; 35: 367–373. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.